Axial Therapeutics Announces Completion of Enrollment in Global Phase 2b Clinical Trial for AB-2004 for Irritability Associated with Autism September 26, 2023
Axial Therapeutics Receives Second Research Grant Award from The Michael J. Fox Foundation to Further Support Advancement of AX-5006 for Parkinson’s Disease June 20, 2023
Axial Therapeutics Announces Age Expansion in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder April 6, 2023
Axial Therapeutics Announces Key R&D Promotions to Advance Clinical and Preclinical Pipeline of Small Molecule Microbiome Therapeutics March 30, 2023
Safety and target engagement of an oral small-molecule sequestrant in adolescents with autism spectrum disorder: an open-label phase 1b/2a trial February 14, 2022
